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OBJECTIVES: Laparoscopic surgery (LS) requires advanced and expensive surgical 
instruments but offers better quality of life and shorten hospitalization compared to 
conventional surgery. This study aimed to evaluate the utilization of LS between 
patients under Civil Servant Medical Beneﬁ t scheme (CSMBS) and those under Uni-
versal Coverage scheme (UC) and to determine the factors associated with the provi-
sion of LS in most common diseases. METHODS: A hospital data of patients 
undergoing LS were obtained from the Central Ofﬁ ce for Healthcare Information. The 
database contained 686,553 admissions with principle diagnoses related to LS from 
January 2005 to December 2007. Descriptive analyses and binary logistic regression 
models were used to analyze the data. RESULTS: The total of 24,175 hospitalizations 
(3.52%) was operated with LS. The proportion of CSMBS patients undergoing LS 
(7.8%) was higher than that of UC patients (2.68%). It was found that diseases of 
gallbladder and cholecystitis, diseases of gynecology and acute appendicitis were the 
most diseases performing LS in Thailand. The provision of LS was signiﬁ cantly associ-
ated with age, sex, principal diagnosis, admission year, type of hospitals and type of 
health insurance coverage. Patients with CSMBS were about two or three times more 
likely to undergo LS compared to UC. Type of health insurance was the most signiﬁ -
cant factor associated with the use of LS. CONCLUSIONS: There is an unequal access 
to LS among patients owing to both medical and nonmedical indications. Health 
insurance coverage plays a signiﬁ cant role in LS provision in Thailand. 
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OBJECTIVES: In India, medicines are dispensed free in the public sector facilities. 
However, due to low availability of medicines in the public facilities, 80% of health-
care expenditure is out-of-pocket. The survey was conducted to investigate the pro-
curement system and distribution of medicines in the public sector and supply chain 
in private sector in National Capital Territory of Delhi (NCT, Delhi). METHODS: 
The majority of public health care in Delhi is provided by central government and the 
government of NCT Delhi; there are two additional public sector providers, Municipal 
Corporation of Delhi and New Delhi Municipal Corporation of Delhi. Procurement 
system and distribution in each of the four public sectors was studied. For private 
sector data was collected from reliable wholesalers and retailers by liaising with their 
association to know the details of mark ups in the supply chain. RESULTS: Each 
public sector entity has its own procurement list and procurement system. Procurement 
for central government hospitals and dispensaries is handled separately by a govern-
ment agency that charges fees. In case of stock outs or non-availability of rate control 
of medicines tertiary care hospitals and central government dispensaries can do local 
purchase. Medicines bought as local purchases are usually more costly and rarely 
undergo the same quality assurance checks. In the private sector medicine distribution 
is characterized by a high number of generic equivalents and high levels of competition 
at each level of the system. Manufacturer can only sell to a licensed wholesaler; 
wholesaler can only sell to licensed retailers. Trade schemes run between manufac-
turer, wholesaler and retailer. CONCLUSIONS: Several strengths and weaknesses in 
the public procurement systems were observed. Huge amount of local purchases were 
reported. Patients do not get beneﬁ t from trade schemes; manufacturers and retailers 
are the beneﬁ ciary. Policy and regulatory interventions are needed to improve access 
and affordability of medicines. 
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OBJECTIVES: To assess and analyze the number, type, and extent of risk-sharing 
agreements worldwide based on published literature. METHODS: A structured litera-
ture review using predeﬁ ned search criteria was conducted to identify references to, 
or descriptions of, health outcome-based risk-sharing agreements within peer-reviewed 
and trade publications between the years of 2000–2010. The identiﬁ ed publications 
were categorized by strength of evidence (i.e., systematic or non-systematic), and then 
aggregated by type of agreement, technology, and companies involved within the 
agreement. Analysis was completed to demonstrate commonalities among identiﬁ ed 
agreements as well as their unique aspects. RESULTS: Five database and publication 
sources were reviewed using 17 predeﬁ ned search terms. The literature review suggests 
that many risk-sharing agreements are not published and those that are vary widely 
in design, scope, and intent. The search resulted in 61 abstracts which identiﬁ ed eight 
individual published risk-sharing schemes. While all identiﬁ ed agreements link 
improvements in health outcomes with reimbursement, deﬁ nitions of what constitutes 
improved health outcomes, as well as the type of evidence required to prove that 
improvement, varied dramatically. The published risk-sharing schemes were from the 
UK (n = 3), United States (n = 3), France (n = 1), and Sweden (n = 1). There is more 
publically available information on agreements outside of the United States, but it is 
unclear the extent to which this is due to greater transparency in reimbursement versus 
a reﬂ ection of more risk-sharing agreements. CONCLUSIONS: Health outcomes-
based risk-sharing agreements offer the potential for both beneﬁ t and frustration to 
manufacturers and payers alike. The ability to review progress within this ﬁ eld to-date 
and attempt to offer trends toward best practices will be key to the long-term viability 
of these novel reimbursement efforts. Despite the heterogeneity of agreement types, 
methods, and foci, successful utilization of these agreements has been achieved and 
could potentially offer a guide for replication in future use. 
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OBJECTIVES: It is commonly believed that after the patent expires for a branded 
pharmaceutical, the average price for the generic compound falls following generic 
entry into the market. The objectives of this study were to 1) determine and explain 
the trend in drug price post-entry, and 2) predict the number of generic-company 
entrants, one of the most likely factors inﬂ uencing price; and to accomplish 1) and 2) 
in a more comprehensive manner than previously in the literature. METHODS: 
Quarterly transaction-price data were constructed using the national summary ﬁ le of 
Medicaid outpatient drug utilization maintained by the Centers for Medicare and 
Medicaid Services. Data from 1991–2008 were extracted for 65 drugs that experi-
enced initial generic entry between 1992 and 2004. Generic relative price (GRP) was 
constructed as reimbursement per unit for a speciﬁ c ﬁ rm and quarter divided by 
average reimbursement per unit over the year before entry, not accounting for phar-
maceutical manufacturer rebates. Least-squares regression models were estimated on 
the panel data to explain GRP, average GRP across ﬁ rms (AGRP), and number of 
entrants. RESULTS: The number of ﬁ rms had a statistically signiﬁ cant (P < 0.0001), 
nonlinear negative effect on GRP and AGRP. High demand, as indicated by high 
post-entry expenditures, had a statistically signiﬁ cant (P < 0.0001) positive effect on 
both GRP and AGRP. Statistically signiﬁ cant (P < 0.0001) predictors for number of 
entrants included pre-entry market size, number of quarters since entry, and admin-
istration form (oral, injectable, or topical) of the drug. Evidence suggests as well that 
rebranding following generic entry commands a price premium. CONCLUSIONS: 
This study generally supports the common wisdom, from prior econometric studies, 
that drug prices fall following generic entry. However, other factors, such as small 
market size or rebranding, can mitigate or even reverse the post-entry price drop, 
reducing the ability of payers to beneﬁ t from signiﬁ cant cost savings. 
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OBJECTIVES: Medication reconciliation is the process to review patients’ complete 
medication regiments at all the time of transitions of care and compare patients’ exist-
ing and previous medication with the regiments being considered for the new setting 
of care. The objective of this study is to implement medication reconciliation to reduce 
drug-therapy problems and errors, and to evaluate the ﬁ nancial impact of these 
approaches in Taiwan. METHODS: The criteria for cases recruiting in this study were 
patients staying in the academic medical center for more than 3 days. Nevertheless, 
the patients with cancer or admitted to the ICU were excluded. Pharmacists reviewed 
the patients’ admission charts and compared the patients’ medication regiments at 
present and past. Once the inconsistence medications were identiﬁ ed, pharmacists 
would discuss with the multispecialty team consisting of physicians, pharmacists and 
nurses to ensure if therapy should be adjusted. The determination of ﬁ nancial impact 
is expressed by cost avoidance per year in Taiwan. RESULTS: The data from the study 
suggests approximately 11.07% of drug-related problems were identiﬁ ed and pre-
vented by pharmacists through medication reconciliation. This can be translated into 
approximately 350,697 episodes per year in Taiwan (based on the assumption for 
total hospitalization of about 3,168,000 persons per year). The estimated cost avoid-
ance will be as high as NT 1941 million per year (based on the assumption for cost 
of prolonged length of hospital stay is about NT 5000) through achieving the medica-
tion reconciliation at admission. CONCLUSIONS: This study demonstrated that the 
pharmacists’ interventions were able to prevent potential adverse drug events, recon-
cile discrepancies among medications, and reduce medical expenditure as well. Effec-
tive assurance in medication safety is also achieved through the collaboration of 
multiple disciplines in patient care. 
